Literature DB >> 21156006

EGFR overexpression induces activation of telomerase via PI3K/AKT-mediated phosphorylation and transcriptional regulation through Hif1-alpha in a cellular model of oral-esophageal carcinogenesis.

Steffen Heeg1, Nina Hirt, Angela Queisser, Hannah Schmieg, Michaela Thaler, Heike Kunert, Michael Quante, Gitta Goessel, Alexander von Werder, Jan Harder, Roderick Beijersbergen, Hubert E Blum, Hiroshi Nakagawa, Oliver G Opitz.   

Abstract

Telomerase plays an important role during immortalization and malignant transformation as crucial steps in the development of human cancer. In a cellular model of oral-esophageal carcinogenesis, recapitulating the human disease, immortalization occurred independent of the activation of telomerase but through the recombination-based alternative lengthening of telomeres (ALT). In this stepwise model, additional overexpression of EGFR led to in vitro transformation and activation of telomerase with homogeneous telomere elongation in already immortalized oral squamous epithelial cells (OKF6-D1_dnp53). More interestingly, EGFR overexpression activated the PI3K/AKT pathway. This strongly suggested a role for telomerase in tumor progression in addition to just elongating telomeres and inferring an immortalized state. Therefore, we sought to identify the regulatory mechanisms involved in this activation of telomerase and in vitro transformation induced by EGFR. In the present study we demonstrate that telomerase expression and activity are induced through both direct phosphorylation of hTERT by phospho-AKT as well as PI3K-dependent transcriptional regulation involving Hif1-alpha as a key transcription factor. Furthermore, EGFR overexpression enhanced cell cycle progression and proliferation via phosphorylation and translocation of p21. Whereas immortalization was induced by ALT, in vitro transformation was associated with telomerase activation, supporting an additional role for telomerase in tumor progression besides elongating telomeres.
© 2010 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156006     DOI: 10.1111/j.1349-7006.2010.01796.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  21 in total

Review 1.  PTEN regulation of ERK1/2 signaling in cancer.

Authors:  Mahandranauth A Chetram; Cimona V Hinton
Journal:  J Recept Signal Transduct Res       Date:  2012-06-28       Impact factor: 2.092

2.  Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.

Authors:  Ren-Chin Wu; Ayse Ayhan; Daichi Maeda; Kyu-Rae Kim; Blaise A Clarke; Patricia Shaw; Michael Herman Chui; Barry Rosen; Ie-Ming Shih; Tian-Li Wang
Journal:  J Pathol       Date:  2014-03       Impact factor: 7.996

3.  The paternal age at conception effect on offspring telomere length: mechanistic, comparative and adaptive perspectives.

Authors:  Dan T A Eisenberg; Christopher W Kuzawa
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-03-05       Impact factor: 6.237

Review 4.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

Review 5.  The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.

Authors:  Wilhelm Engström; Philippa Darbre; Staffan Eriksson; Linda Gulliver; Tove Hultman; Michalis V Karamouzis; James E Klaunig; Rekha Mehta; Kim Moorwood; Thomas Sanderson; Hideko Sone; Pankaj Vadgama; Gerard Wagemaker; Andrew Ward; Neetu Singh; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

6.  Telomere length and recurrence risk after curative resection in patients with early-stage non-small-cell lung cancer: a prospective cohort study.

Authors:  Eric S Kim; Yuanqing Ye; Ara A Vaporciyan; Jinliang Xing; Maosheng Huang; Jian Gu; Jack A Roth; Scott M Lippman; Xifeng Wu
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

7.  Association of PYGO2 and EGFR in esophageal squamous cell carcinoma.

Authors:  Meysam Moghbeli; Mohammad Reza Abbaszadegan; Moein Farshchian; Mehdi Montazer; Reza Raeisossadati; Abbas Abdollahi; Mohammad Mahdi Forghanifard
Journal:  Med Oncol       Date:  2013-03-03       Impact factor: 3.064

8.  Association between leukocyte telomere length and glioma risk: a case-control study.

Authors:  Shaolong Wang; Yibing Chen; Falin Qu; Shiming He; Xiaojun Huang; Hequn Jiang; Tianbo Jin; Shaogui Wan; Jinliang Xing
Journal:  Neuro Oncol       Date:  2013-12-22       Impact factor: 12.300

9.  Increased telomerase activity and hTERT expression in human salivary gland carcinomas.

Authors:  Hideo Shigeishi; Masaru Sugiyama; Hidetoshi Tahara; Shigehiro Ono; Ujjal Kumar Bhawal; Masaya Okura; Mikihiko Kogo; Masanori Shinohara; Masanobu Shindoh; Satoru Shintani; Hiroyuki Hamakawa; Takashi Takata; Nobuyuki Kamata
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

Review 10.  Pathophysiological mechanisms of death resistance in colorectal carcinoma.

Authors:  Ching-Ying Huang; Linda Chia-Hui Yu
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.